![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/sumitovant-subsidiaries-enzyvant-and-altavant-merge-into-combined-company/
https://www.prnewswire.com/news-releases/altavant-sciences-presents-data-showing-potential-for-combination-of-rodatristat-ethyl-and-ambrisentan-in-model-of-pulmonary-arterial-hypertension-301541434.html
https://www.prnewswire.com/news-releases/altavant-sciences-presented-data-at-ishlt-showing-potency-and-distribution-of-bronchiolitis-obliterans-candidate-alta-2530-301536741.html
https://www.prnewswire.com/news-releases/altavant-sciences-to-present-data-at-ishlt-showing-potency-and-distribution-of-bronchiolitis-obliterans-candidate-alta-2530-301532140.html
https://www.prnewswire.com/news-releases/altavant-sciences-highlights-ongoing-phase-2b-elevate-2-study-of-rodatristat-ethyl-in-patients-with-pulmonary-arterial-hypertension-at-european-respiratory-society-annual-congress-301375357.html
https://www.biospace.com/article/releases/altavant-sciences-reports-rodatristat-ethyl-pk-pd-analysis-at-ats-supporting-doses-selected-for-phase-2b-elevate-2-study/
https://www.prnewswire.com/news-releases/altavant-sciences-provides-update-on-clinical-plan-for-pah-candidate-rodatristat-ethyl-at-upcoming-american-thoracic-society-annual-meeting-301287860.html#:~:text=CARY%2C%20N.C.%20and%20BASEL%2C%20Switzerland,company's%20lead%20candidate%20for%20the
https://www.prnewswire.com/news-releases/altavant-sciences-provides-update-on-clinical-plan-for-pah-candidate-rodatristat-ethyl-at-upcoming-american-thoracic-society-annual-meeting-301287860.html
https://www.globenewswire.com/news-release/2021/04/26/2217045/0/en/Cary-N-C-and-Basel-Switzerland-s-Finds-Nebulized-ALTA-2530-Retains-Potency-and-Reaches-Target-Lung-Tissues-Supporting-Continued-Investigation-for-Treatment-of-BOS.html
https://www.globenewswire.com/news-release/2020/08/05/2073316/0/en/Altavant-Sciences-Presentation-at-ATS-2020-Confirms-Minimal-Brain-Exposure-of-Peripherally-Acting-Serotonin-Modulator-Rodatristat-Ethyl-in-Clinical-Development-for-PAH.html